A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2002
10/24/2002	US20020156050 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors
10/24/2002	US20020156040 Antisense oligonucleotides that bind to the enzyme's start codon; inhibiting enzymes such as superoxide dismutase
10/24/2002	US20020156036 Expression vector encoding a fusion protein with segments of a region which binds to an epitope or fragment and fragment or whole proteins that can cross the blood brain barrier
10/24/2002	US20020156027 Ketolide antibiotics
10/24/2002	US20020156007 Apolipoprotein analogues
10/24/2002	US20020156000 Inhibiting NF-kappa B-dependent target gene expression in a cell.
10/24/2002	US20020155988 Uses of transport proteins
10/24/2002	US20020155547 Polypeptide for use in the treatment of cancer, hepatitis, multiple sclerosis, fibrosis, inflammatory or autoimmune diseases, cancers and viral diseases
10/24/2002	US20020155539 Calcium channel polynucleotides, polypeptides, and antibodies
10/24/2002	US20020155534 SBHWSB2: a new member of the WD40 SOCS box family
10/24/2002	US20020155532 Method of producing biologically active human acidic fibroblast growth factor and its use in promotiong angiogenesis
10/24/2002	US20020155528 Regulation of human CysLT2-like GPCR protein
10/24/2002	US20020155432 Genetically engineered herpes virus for the treatment of cardiovascular disease
10/24/2002	US20020155181 Method and composition for improving sexual fitness
10/24/2002	US20020155101 Cardiac arrhythmia treatment methods
10/24/2002	US20020155091 For reducing serum cholesterol in a mammal
10/24/2002	US20020155067 For drug delivery
10/24/2002	DE10113604A1 Verfahren zur Spaltung des humanen Wachstumshormons GH A process for cleavage of human growth hormone GH
10/24/2002	CA2490819A1 Compounds useful as anti-inflammatory agents
10/24/2002	CA2445990A1 Full-length human cdnas encoding potentially secreted proteins
10/24/2002	CA2445538A1 Oxalic acid derivatives
10/24/2002	CA2444632A1 Vascular endothelial growth factor 2
10/24/2002	CA2444596A1 Large conductance calcium-activated k channel opener
10/24/2002	CA2444481A1 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
10/24/2002	CA2444465A1 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
10/24/2002	CA2444253A1 Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae
10/24/2002	CA2444247A1 Inhibitors of integrin .alpha.v.beta.6
10/24/2002	CA2444220A1 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine
10/24/2002	CA2444164A1 Pufa polyketide synthase systems and uses thereof
10/24/2002	CA2443995A1 Endothelial cell expression patterns
10/24/2002	CA2443993A1 Methods and reagents for cell transplantation
10/24/2002	CA2443984A1 Encapsulated cell indicator system
10/24/2002	CA2443897A1 Transporters and ion channels
10/24/2002	CA2443870A1 Cyclohexylphenyl vasopressin agonists
10/24/2002	CA2443805A1 Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
10/24/2002	CA2443726A1 Use of the protein uk114 or of fragments thereof for the treatment and prevention of the endotoxic shock
10/24/2002	CA2443709A1 Novel cyclo azaphospha hydrocarbons
10/24/2002	CA2443699A1 Phenyl heterocyclyl ether
10/24/2002	CA2443697A1 1,4-disubstituted benzo-fused compounds
10/24/2002	CA2443577A1 Nicotinic acetylcholine receptor ligands
10/24/2002	CA2443568A1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepi ne-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/24/2002	CA2443487A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	CA2443477A1 New process for the preparation of oxabispidines
10/24/2002	CA2443475A1 New process for the preparation of oxabispidines
10/24/2002	CA2443473A1 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds
10/24/2002	CA2443470A1 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds
10/24/2002	CA2443468A1 Pharmaceutical product with reticulated crystalline microstructure
10/24/2002	CA2443464A1 3,7-diazybicyclo [3.3.1] formulations as antiarrhytmic compounds
10/24/2002	CA2443408A1 Kinases and phosphatases
10/24/2002	CA2443244A1 Enzymes
10/24/2002	CA2443234A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	CA2442953A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation
10/24/2002	CA2438107A1 G-protein coupled receptor molecules and uses thereof
10/24/2002	CA2431553A1 Cxcr3 antagonists
10/23/2002	EP1251177A2 Cytokine-, stress-, and oncoprotein-activited human protein kinase kinases
10/23/2002	EP1251176A2 Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
10/23/2002	EP1251170A2 Method and reagent for treatment of NF-kappaB dependent animal diseases
10/23/2002	EP1251137A2 Use of insulin-like growth factor agonist peptides
10/23/2002	EP1250935A1 REMEDIES FOR REPERFUSION INJURY CONTAINING INTEGRIN ALPHAvBETA3 ANTAGONIST
10/23/2002	EP1250927A2 Pharmaceutical composition for topical application comprising nifedipine
10/23/2002	EP1250328A1 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
10/23/2002	EP1250326A2 Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
10/23/2002	EP1250325A1 Phenanthridine-n-oxides
10/23/2002	EP1250323A2 Compounds having hypolipidemic and hypocholesterolemic activities, process for their preparation and pharmaceutical compositions containing them
10/23/2002	EP1250317A2 Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments
10/23/2002	EP1250166A1 Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
10/23/2002	EP1250157A1 Antisense modulation of inducible nitric oxide synthase expression
10/23/2002	EP1250156A1 Method for nucleic acid transfection of cells
10/23/2002	EP1250155A1 Angiogenesis and vascular permeability modulators and inhibitors
10/23/2002	EP1250151A1 Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis
10/23/2002	EP1250142A1 Multivalent electron active compositions and methods of making and using same
10/23/2002	EP1250141A1 Prevention and treatment of endotoxemia and related complications associated with surgery
10/23/2002	EP1250140A2 Combinations of a receptor tyrosine kinase inhibitor with alpha1-acidic glycoprotein binding compound
10/23/2002	EP1250116A1 Pharmaceutical and cosmetic carrier or composition for topical application
10/23/2002	EP1250092A1 Novel dyes
10/23/2002	EP1140191B1 Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
10/23/2002	EP1000067B1 Thiazolobenzoheterocycles, preparation and medicines containing same
10/23/2002	EP0925303B1 Phosphinic acid amides as matrix metalloprotease inhibitors
10/23/2002	EP0894089B1 Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
10/23/2002	EP0767170B1 Novel 4,6-diarylpyrimidine derivatives and salts thereof
10/23/2002	EP0723552B1 Oligopeptides derived from c-reactive protein fragments
10/23/2002	CN1376197A Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
10/23/2002	CN1376166A Peptide that lower blood glucose levels
10/23/2002	CN1376162A Novel techykinin peptides, precursor peptides thereof and genes encoding the same
10/23/2002	CN1376160A Novel macrolide antibiotics
10/23/2002	CN1376157A Triazolopurine derivatives, drug compositions containing the same and adenosine A3 receptor affinitive agents
10/23/2002	CN1376156A Benzodiazepin derivatives, the production and use thereof
10/23/2002	CN1376146A Solid-state form of celecoxil having enhanced bioavailability
10/23/2002	CN1376144A Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
10/23/2002	CN1376072A Metabolic intervention with GLP-1 or its biologically active analygues to improve the function of the ischemic and reperfused brain
10/23/2002	CN1376055A Aerosol ointment compositions and method of manufacture
10/23/2002	CN1376036A Metal-containing compositions, preparations and uses
10/23/2002	CN1375494A Iso-indolo-indolone compound, their preparation methods and drug compositions comprising the same
10/23/2002	CN1375316A Chinese medicine prepn. for treating coronary heart disease and angina pactoris and its prepn. process
10/23/2002	CN1375314A Fermented soybean extracted liquid and composite medicine containing the said liquid
10/23/2002	CN1375309A Hypertension treating medicine capable of protecting target organ and its production process
10/23/2002	CN1375299A Hemiplegia-treating Chinese medicine and its prepn.
10/23/2002	CN1375288A Composite medicine for treating cerebrovascular diseases
10/23/2002	CN1375209A Healthy tea
10/23/2002	CN1093128C Process for preparing eprosartan

1 ... 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 ... 1595